Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 in Refractory Hypercalcemia of Malignancy
NCT04198480Phase 2Terminated
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of narlumosbart in hypercalcemia of malignancy (HCM), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL Within 10 Days after First Dose of JMT103. Started Apr 2020; status: terminated.
02
Drugs
narlumosbart
03
Conditions
hypercalcemia of malignancy (HCM)
Beyond the preview
Go deeper on NCT04198480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198480.